Top

Published in:

Open Access 01-12-2018 | Original research

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

Published in: EJNMMI Research | Issue 1/2018

Abstract

Background

I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Seven of these patients undergoing sorafenib/immunotherapy with 2.5 or 5 mg/kg of cold codrituzumab had repeat imaging, with co-infusion of I-124 codrituzumab, as part of their immunotherapy treatment. Three patients who progressed while on sorafenib/immunotherapy were re-imaged after a 4-week washout period to assess for the presence of antigen. Serial positron emission tomography (PET) imaging and pharmacokinetics were performed following I-124 codrituzumab. An ELISA assay was used to determine “cold” codrituzumab serum pharmacokinetics and compare it to that of I-124 codrituzumab. Correlation of imaging results was performed with IHC. Short-term safety assessment was also evaluated.

Results

Thirteen patients had tumor localization on baseline I-124 codrituzumab; heterogeneity in tumor uptake was noted. In three patients undergoing repeat imaging while on immunotherapy/sorafenib, evidence of decreased I-124 codrituzumab uptake was noted. All three patients who underwent imaging after progression while on immunotherapy continued to have I-124 codrituzumab tumor uptake. Pharmacokinetics of I-124 codrituzumab was similar to that of other intact IgG. No significant adverse events were observed related to the I-124 codrituzumab.

Conclusions

I-124 codrituzumab detected tumor localization in most patients with HCC. Pharmacokinetics was similar to that of other intact iodinated humanized IgG. No visible cross-reactivity with normal organs was observed.

Available only for authorised users

Ayyar BV, Arora S, O’Kennedy R. Coming-of-age of antibodies in cancer therapeutics. Trends Pharmacol Sci. 2016;37:1009–28. https://doi.org/10.1016/j.tips.2016.09.005.CrossRefPubMed

Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with F-18-FDG PET. J Nucl Med. 2006;47:793–6.PubMedPubMedCentral

Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22(6):701. https://doi.org/10.1038/nbt968.CrossRefPubMed

Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27:619–24. https://doi.org/10.1093/annonc/mdv577.CrossRefPubMed

Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, et al. (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011;52:1173–80. https://doi.org/10.2967/jnumed.110.086165.CrossRefPubMedPubMedCentral

Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31:187–94. https://doi.org/10.1200/jco.2011.41.2445.CrossRefPubMed

Arbit E, Cheung NKV, Yeh SDJ, Daghighian F, Zhang JJ, Cordoncardo C, et al. Quantitative studies of monoclonal-antibody targeting to disialoganglioside G(D2) in human brain tumors. Eur J Nucl Med. 1995;22:419–26.CrossRefPubMed

O’Donoghue JA, Smith-Jones PM, Humm JL, Ruan ST, Pryma DA, Jungbluth AA, et al. I-124-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med. 2011;52:1878–85. https://doi.org/10.2967/jnumed.111.095596.CrossRefPubMedPubMedCentral

Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O’Donoghue JA, Humm JL, Smith-Jones P, et al. PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. Eur J Nucl Med Mol Imaging. 2015;42:1700–6. https://doi.org/10.1007/s00259-015-3061-2.CrossRefPubMedPubMedCentral

10.

Beylergil V, Morris PG, Smith-Jones PM, Modi S, Solit D, Hudis CA, et al. Pilot study of Ga-68-DOTA-F(ab′)(2)-trastuzumab in patients with breast cancer. Nucl Med Commun. 2013;34:1157–65. https://doi.org/10.1097/MNM.0b013e328365d99b.PubMedPubMedCentral

11.

Carrasquillo JA, Morris PG, Humm JL, Smith-Jones PM, Beylergil V, Akhurst T, et al. Copper-64 trastuzumab PET imaging: a reproducibility study. Q J Nucl Med Mol Imaging. 2016; [Epub ahead of print]

12.

Dijkers EC, Munnink THO, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of Zr-89-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586–92. https://doi.org/10.1038/clpt.2010.12.CrossRefPubMed

13.

Pandit-Taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan ST, Solomon SB, et al. Zr-89-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:2093–105. https://doi.org/10.1007/s00259-014-2830-7.CrossRefPubMedPubMedCentral

14.

Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, et al. A prospective pilot study of Zr-89-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2014;191:1439–45. https://doi.org/10.1016/j.juro.2013.10.041.CrossRefPubMed

15.

Pandit-Taskar N, O’Donoghue JA, Ruan ST, Lyashchenko SK, Carrasquillo JA, Heller G, et al. First-in-human imaging with Zr-89-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med. 2016;57:1858–64. https://doi.org/10.2967/jnumed.116.176206.CrossRefPubMedPubMedCentral

16.

Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT. J Nucl Med. 2016;57:1523–8. https://doi.org/10.2967/jnumed.115.172031.CrossRefPubMedPubMedCentral

17.

Hanaoka H, Nagaya T, Sato K, Nakamura Y, Watanabe R, Harada T, et al. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Mol Pharm. 2015;12:2151–7. https://doi.org/10.1021/acs.molpharmaceut.5b00132.CrossRefPubMed

18.

Yang X, Liu H, Sun CK, Natarajan A, Hu X, Wang X, et al. Imaging of hepatocellular carcinoma patient-derived xenografts using Zr-89-labeled anti-glypican-3 monoclonal antibody. Biomaterials. 2014;35:6964–71. https://doi.org/10.1016/j.biomaterials.2014.04.089.CrossRefPubMedPubMedCentral

19.

Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001;108:497–501. https://doi.org/10.1172/jci13712.CrossRefPubMedPubMedCentral

20.

Feng MQ, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014;588:377–82. https://doi.org/10.1016/j.febslet.2013.10.002.CrossRefPubMed

21.

Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89–97. https://doi.org/10.1016/s0016-5085(03)00689-9.CrossRefPubMed

22.

Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013;19:920–8. https://doi.org/10.1158/1078-0432.ccr-12-2616.CrossRefPubMed

23.

Yorita K, Takahashi N, Takai H, Kato A, Suzuki M, Ishiguro T, et al. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int. 2011;31:120–31. https://doi.org/10.1111/j.1478-3231.2010.02359.x.CrossRefPubMed

24.

Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, et al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anti-Cancer Drugs. 2010;21:907–16. https://doi.org/10.1097/CAD.0b013e32833f5d68.CrossRefPubMed

25.

Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008;68:9832–8. https://doi.org/10.1158/0008-5472.can-08-1973.CrossRefPubMed

26.

Ikeda M, Ohkawa S, Okusaka T, Mitsunaga S, Kobayashi S, Morizane C, et al. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci. 2014;105:455–62. https://doi.org/10.1111/cas.12368.CrossRefPubMedPubMedCentral

27.

Abou-Alfa GK, Yen CJ, Hsu CH, O’Donoghue J, Beylergil V, Ruan ST, et al. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemother Pharmacol. 2017;79:421–9. https://doi.org/10.1007/s00280-017-3241-9.CrossRefPubMedPubMedCentral

28.

Finn R, Balatoni J, Kothari P, Pentlow K, Sheh Y, Lom C, et al. Cyclotron production and potential clinical application of iodine-124 labeled radiotracers. In: Duggan JL, Morgan IL, editors. Application of accelerators in research and industry; 2001. p. 849–52.

29.

Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77–89.CrossRefPubMed

30.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed

31.

Barrett PHR, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: stimulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484–92.CrossRefPubMed

32.

Retzlaff JA, Tauxe WN, Kiely JM, Stroebel CF. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood. 1969;33:649–61.PubMed

33.

KS MC Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46:4244s–8s.

34.

Haruyama Y, Yorita K, Yamaguchi T, Kitajima S, Amano J, Ohtomo T, et al. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer. 2015;137:1643–51. https://doi.org/10.1002/ijc.29518.CrossRefPubMed

35.

Naruki Y, Carrasquillo JA, Reynolds JC, Maloney PJ, Frincke JM, Neumann RD, et al. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. Int J Rad Appl Instrum B. 1990;17:201–7.CrossRefPubMed

36.

Yao ZS, Garmestani K, Wong KJ, Park LS, Dadachova E, Yordanov A, et al. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med. 2001;42:1538–44.PubMed

37.

Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, et al. Pairwise comparison of (89)Zr- and (124)I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:985–94. https://doi.org/10.1007/s00259-013-2679-1.CrossRefPubMedPubMedCentral

38.

Divgi CR, O’Donoghue JA, Welt S, O’Neel J, Finn R, Motzer RJ, et al. Phase I clinical trial with fractionated radioimmunotherapy using I-13-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004;45:1412–21.PubMed

Title: I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
Publication date: 01-12-2018
Published in: EJNMMI Research / Issue 1/2018
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-018-0374-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

Abstract

Background

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

[18F]DPA-714 PET imaging shows immunomodulatory effect of intravenous administration of bone marrow stromal cells after transient focal ischemia

Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis

Comparison of three-parameter kinetic model analysis to standard Patlak’s analysis in 18F-FDG PET imaging of lung cancer patients

Volume-of-interest-based supervised cluster analysis for pseudo-reference region selection in [18F]DPA-714 PET imaging of the rat brain

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review

Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model